IBM (NYSE:IBM) announced today that it plans to work with medical institutions and practitioners by offering support in the development of drugs to combat the recent coronavirus outbreak.
The company said in a news release that it intends to leverage its IBM clinical development (ICD) system to help accelerate the development of key drugs in fighting the virus. ICD is a unified, SaaS-based data capture solution designed to offer end-to-end visibility and management capabilities for patients, sites and clinical trials.
ICD is also designed to reduce the time and cost of clinical trials through centralized and organized clinical trial details and a flexible and scalable data management platform.
IBM said its plan to assist in the coronavirus outbreak includes providing the ICD system for free to eligible applicable novel coronavirus-related clinical trials in China. The company also plans to offer commercially reasonable technology for free to support database construction and basic training for using ICD.
The company is among many medical device developers making an effort to help combat the coronavirus. IBM said hospitals, sponsors, CROs and R&D institutions that are researching novel coronavirus drugs and conducting related clinical trials are encouraged to contact the company.
Filed Under: Drug Discovery, Drug Discovery and Development
